## Helen Mann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2120076/publications.pdf

Version: 2024-02-01

1478505 1720034 2,774 7 6 7 citations h-index g-index papers 7 7 7 4209 docs citations citing authors times ranked all docs

| # | Article   | IF   | CITATIONS |
|---|---|------|-----------|
| 1 | Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research, 2021, 95, 100640.  | 1.2  | 1         |
| 2 | Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III<br>Non–Small–Cell Lung Cancer (PACIFIC). Clinical Lung Cancer, 2021, 22, 549-561.   | 2.6  | 25        |
| 3 | Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting. Cancer Epidemiology, 2019, 60, 121-127.   | 1.9  | 26        |
| 4 | Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331.                       | 2.2  | 14        |
| 5 | Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial. Journal of Clinical Oncology, 2018, 36, 1853-1860.  | 1.6  | 32        |
| 6 | Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer. New England Journal of Medicine, 2017, 376, 629-640.  | 27.0 | 2,631     |
| 7 | Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). BMC Cancer, 2015, 15, 467. | 2.6  | 45        |